Bio/Pharma Business

CPHI Annual Report: VC Capital Investment and Contract Services Growth in 2024

October 24, 2023

The report indicates a rise in biotech funding and subsequent growth for pharma contract services.

Royalty Pharma to Purchase up to $1.5 Billion of PTC Therapeutics’ Royalty on Roche’s Evrysdi

October 20, 2023

The spinal muscular atrophy treatment, currently marketed by Roche, generated $1.2 billion in sales in 2022.

Spark Therapeutics Partners with SpliceBio on a Gene Therapy for Eye Disease

October 18, 2023

Spark Therapeutics and SpliceBio have formed a collaboration to develop a gene therapy that can treat an inherited retinal disease.

CIRM Picks Forge Biologics as AAV Manufacturing Partner

October 18, 2023

The California Institute for Regenerative Medicine has partnered with Forge Biologics, which will manufacture AAVs to help accelerate gene therapy programs in California.

Cellares Expands Agreement with Bristol Myers Squibb for Second CAR-T Program

October 13, 2023

Under an expanded agreement, Cellares will provide proof-of-concept manufacturing for a second CAR-T cell therapy from Bristol Myers Squibb.

Bristol Myers Squibb Acquires Mirati Therapeutics for up to $5.8 Billion

October 12, 2023

Mirati’s focus on breakthrough cancer treatments will bolster Bristol Myers Squibb’s oncology portfolio.

Salipro Biotech and Icosagen to Collaborate on Antibody Discovery

October 12, 2023

Salipro Biotech and Icosagen have entered into a multi-target collaboration to discover and characterize monoclonal antibodies.

BIOVECTRA in Tech Transfer Agreement with Acuitas Therapeutics for LNP Delivery System

October 11, 2023

Under this agreement, Acuitas Therapeutics’ LNP technology platform will be transferred to BIOVECTRA for use in manufacturing mRNA-based therapies.

Roche to Develop Two Novel RNA-targeted Programs from Ionis for CNS Diseases

October 11, 2023

Roche will gain exclusive worldwide rights to develop, manufacture, and commercialize Ionis’ investigational RNA-based therapeutic candidates for Alzheimer's and Huntington's disease.

Novartis Completes Sandoz Spin-off

October 10, 2023

Spinning off Sandoz allows Novartis to focus on the areas of cardiovascular, immunology, renal and metabolic, and oncology.